Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX, FPH) has today been advised by Fisher & Paykel Appliances Holdings Limited (FPA) that FPA has successfully completed the bookbuild process in respect of the sale of its 19.34% shareholding in Fisher & Paykel Healthcare Corporation Limited. In view of this, Fisher & Paykel Healthcare Corporation Limited has requested both NZX and ASX to lift the trading halts in respect of its shares, from the opening of the markets today.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of heated humidification products and systems for use in respiratory care and the treatment of obstructive sleep apnea. It also offers an innovative range of patient warming devices and neonatal care products. The company’s products are sold in over 90 countries worldwide.
Further information can be obtained by contacting Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119 at Fisher & Paykel Healthcare Corporation Limited or by visiting the company’s website at www.fphcare.com
Fisher & Paykel Healthcare Requests Trading Halts to be Lifted
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment